FDA
-
-
-
-
-
-
-
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
-
-
-
-
-
-
-
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
-
-
-
-
-
-
-
RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
-
-
-
-
-
-
-
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
-
-
-
-
-
-
-
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
-
-
-
-
-
-
-
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
-
-
-
-
-
-
-
Biocept Reports First Quarter 2021 Financial Results
-
326,457 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

